The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .
Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study.
BACKGROUND Research studies for the treatment of the putative prodromal phase of psychotic disorders have begun to appear . AIMS To obtain preliminary evidence of the short-term efficacy and safety of aripiprazole treatment in people with the psychosis prodrome . METHOD Fifteen participants meeting prodrome criteria ( mean age 17.1 years , s.d.=5.5 ) enrolled in an open-label , single-site trial with fixed-flexible dosing of aripiprazole ( 5 - 30 mg/day ) for 8 weeks . RESULTS In the mixed-effects repeated- measures analysis , improvement from baseline on the Scale of Prodromal Symptoms total score was statistically significant by the first week . No participant converted to psychosis and 13 completed treatment . Neuropsychological measures showed no consistent improvement ; mean weight gain was 1.2 kg . Akathisia emerged in 8 participants , but the mean Barnes Akathisia Scale score fell to baseline levels by the final visit . Adverse events were otherwise minimal . CONCLUSIONS Aripiprazole shows a promising efficacy and safety profile for the psychosis prodrome . Placebo-controlled studies are indicated
The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .